-

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP:

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula business.

Share

Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally.

What is the class period? February 27, 2024 - November 4, 2025

What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula business.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations? According to the complaint, during the class period, defendants failed to disclose: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; and (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated.

Plaintiff alleges that on November 5, 2025, Perrigo announced disappointing financial results for the third quarter ended September 27, 2025. The press release revealed that Perrigo had slashed its fiscal year 2025 outlook "due primarily to infant formula industry dynamics." The same day, Perrigo issued a press release, announcing the Company “is initiating a strategic review of its infant formula business.” The press release revealed Perrigo is “reassessing the Company’s previously announced investment in this business of $240 million” and that the infant formula business had become “less strategic.” On this news, Perrigo’s stock price fell $5.09, or 25.2%, to close at $15.10 per share on November 5, 2025.

What can you do now? You may be eligible to participate in the class action against Perrigo Corporation plc. Shareholders who wish to serve as lead plaintiff for the class must submit their information with the court by January 16, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Perrigo Company plc settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:PRGO

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Did You Lose Money in Stride, Inc.? Contact Robbins LLP for Information About Your Rights Against LRN.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: The company: Stride, Inc. (NYSE: LRN) is a technology company that provides an education platform to deliver online learning to students throughout the U.S. What is the class period? October 22, 2024 - October 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stride during the class period because the Company allegedly misled investors regarding i...

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...

Have You Incurred Financial Losses Due to Jayud Global Logistics Limited Stock Drop? Contact Robbins LLP for Information About the Action You Can Take Against JYD.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Jayud Global Logistics Limited (NASDAQ: JYD) claims to provide a range of worldwide cross-border supply chain solution services. What is the Class Period? April 21, 2023 - April 30, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Jayud securities during the class period because the Company allegedly engaged in a fraudulent stock promotion s...
Back to Newsroom